Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors
Ryvu Therapeutics to Participate in Upcoming Investor Conferences
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.See More